Lovande resultat för Lillys fetmapiller – skapar börsvågor

Eli Lillys viktminskningspiller överträffar förväntningarna i en fas III-studie och visar resultat i nivå med injicerbara läkemedel som Ozempic. Nyheten fick ak...

Mikael Kubista back with new venture after turbulent exit

Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership ...

In-Depth Insights into the Most Useful ZEISS Metrology Expert Tips

Free webinar June 24th, 2025, 9:00-9:45 AM and 5:00-5:45 PM.

Catalent kapar bort 350 tjänster inom genterapi

CDMO-bolaget Catalent säger upp 350 av sina anställda inom genterapiproduktion i USA.

Elisabet Lann blir ny sjukvårdsminister

Efter det plötsliga avhoppet står det nu klar att Elisabet Lann (KD) blir ny sjukvårdsminister.

Reduced heat transfer to the media with media-separated valves

In laboratory automation, many liquids are used that react sensitively to heat. One possible factor for the transfer of heat to the fluid are media-separated so...

Merck KGaA acquires American company in €3.0 billion deal

Germany’s Merck is completing the acquisition of Springwork Therapeutics for 3 billion euros.

Korbinian Löbmann leads scientific meeting on drug formulation: High activity in the field

Korbinian Löbmann has moderated New Updates in Drug Formulation & Bioavailability several times before. Now he is once again taking on the scientific meeting. L...

From pharmacist to life science podcaster – Magnus Lejelöv uses his voice as a tool

Magnus Lejelöv has more than 20 years of experience in the pharmaceutical industry and has conducted nearly two hundred interviews with healthcare professionals...

3 000 ska bort från Australiens största läkemedelsbolag

Det australiensiska läkemedelsjätten CSL genomför sparåtgärder. I planen ingår bland annat att knoppa av bolagets vaccinenhet och minska arbetsstyrkan med 3 000 medarbetare.

Astra Zeneca faces potential multimillion-dollar fines in China

Astra Zeneca could be forced to pay up up to $8 million in fines for allegedly unpaid import duties in China, as the company seeks to rebuild trust following ea...

After the threat of tariffs – Novartis invests 230 billion in the USA

Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines dest...

ZEISS unveils AI-powered Research Data Platform

Collaboration with Boehringer Ingelheim champions the future of personalized eye care.

ZEISS introduces the new Smartzoom 100

The future of digital microscopy for efficient optical inspections.

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)

We desire talent to come here, but are we genuinely welcoming them?

Sweden faces significant challenges in creating a truly inclusive environment that makes international professionals feel welcome, valued, and able to build mea...

The key to successful collaboration between industry and academia

Why is collaboration between industry and academia necessary in the life sciences sector? What obstacles exist, and what is the key to successful collaboration?

New moves around Nykode's management – withdrawal of resignations

Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.

High-performance Slide Scanner for Fluorescence, Brightfield and Polarization

ZEISS Axioscan 7.

CSL miljardsatsar på ny behandling inom blodkoagulation

Australiensiska CSL har förvärvat en exklusiv option att köpa nederländska Varmx och dess läkemedelskandidat inom blodkoagulation. Affären kan potentiellt uppgå...

Discover Precision: Join ZEISS at the Control Fair in Stuttgart

May 6-9, 2025 in Stuttgart. Hall 9, Booth 9309.

CT technology for when the inside matters

ZEISS METROTOM 1 now at #HandsOnMetrology.

Tirzepatide approved for obesity by the FDA – to be branded as Zepbound

Diabetes drug tirzepatide has now also been approved in the US for treating obesity.

Orexo får USA-stöd för överdosläkemedel vid blandmissbruk

Uppsalabolaget Orexo har fått 8 miljoner dollar, motsvarande 75 miljoner kronor, av den amerikanska myndigheten Barda för att ta fram ett nasalt räddningsläkeme...